Comparison of gallium and PET scans at diagnosis and follow-up of pediatric patients with hodgkin lymphoma

Pediatric Blood and Cancer

Volumn 51, Issue 2, 2008, Pages 198-203

  Hines Thomas, Melissa ^a   Kaste, Sue C ^b,c   Hudson, Melissa M ^b,c   Howard, Scott C ^b,c   Liu, Wei A ^b   Wu, Jianrong ^b   Kun, Larry E ^b,c   Shulkin, Barry L ^b,c   Krasin, Matthew J ^b,c   Metzger, Monika L ^b,c  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

CT scan; Gallium scan; Hodgkin lymphoma; PET scan

Indexed keywords

GALLIUM; DIAGNOSTIC AGENT;

ADOLESCENT; ARTICLE; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CANCER STAGING; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT RESPONSE; INFANT; PRESCHOOL CHILD; SCINTISCANNING;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GALLIUM RADIOISOTOPES; HODGKIN DISEASE; HUMANS; INFANT; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 45549090622     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21574     Document Type: Article

References (46)

1. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: Detection with FDG PET versus CT. Radiology 1998;206:475-481.
2. Patton JA, Delbeke D, Sandler MP. Image fusion using an integrated, dual-head coincidence camera with X-ray tube-based attenuation maps. J Nucl Med 2000;41:1364-1368.
3. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795-800.
4. Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181-1184.
5. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997;38:343-348.
6. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-433.
7. Stumpe KD, Urbinelli M, Steinert HC, et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-728.
8. Schoder H, Meta J, Yap C, et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001;42:1139-1143.
9. Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004;90:620-625.
10. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-59.
11. Hudson MM, Krasin MJ, Kaste SC. PET imaging in pediatric Hodgkin's lymphoma. Pediatr Radiol 2004;34:190-198.
12. Hoekstra OS, Ossenkoppele GJ, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993;34:1706-1710.
13. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, et al. Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma. Radiologe 1997;37:74-80.
14. Kostakoglu L, Leonard JP, Kuji I, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002;94:879-888.
15. Van Den Bossche B, Lambert B, De Winter F, et al. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl Med Commun 2002;23:1079-1083.
16. Bar-Shalom R, Mor M, Yefremov N, et al. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Semin Nucl Med 2001;31:177-190.
17. Zijlstra JM, Hoekstra OS, Raijmakers PG, et al. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2003;123:454-462.
18. Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison. Leuk Lymphoma 2004;45:85-92.
19. Rini JN, Nunez R, Nichols K, et al. Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin's disease. Pediatr Radiol 2005;35:169-178.
20. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006;47:1326-1334.
21. Spaepen K, Stroobants S, Verhoef G, et al. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003;30:S97-S105.
22. Rifai AA, Bazarbashi S, Kandil A. Positron emission tomography in Hodgkin's disease. Correlation with computed tomography and gallium 67 citrate imaging. Clin Positron Imaging 2000;3:179.
23. Malamitsi J, Kosmidis H, Valotassiou B, et al. Negative gallium-67 citrate and positive positron emission tomography/computed tomography spleen scans, in Hodgkin's stage IV lymphoma. Hell J Nucl Med 2007;10:116-118.
24. Willkomm P, Palmedo H, Grunwald F, et al. Functional imaging of Hodgkin's disease with FDG-PETand gallium-67. Nuklearmedizin 1998;37:251-253.
25. Mody RJ, Bui C, Hutchinson RJ, et al. Comparison of (18)F flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. Leuk Lymphoma 2007;48:699-707.
26. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1861.
27. Levine JM, Weiner M, Kelly KM. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol 2006;28:711-714.
28. Hernandez-Pampaloni M, Takalkar A, Yu JQ, et al. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol 2006;36:524-531.
29. Meany HJ, Gidvani VK, Minniti CP. Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 2007;48:399-402.
30. Depas G, De Barsy C, Jerusalem G, et al. 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 2005;32:31-38.
31. Montravers F, McNamara D, Landman-Parker J, et al. [(18)F]FDG in childhood lymphoma: Clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002;29:1155-1165.
32. Johnston GS, Go MF, Benua RS, et al. Gallium-67 citrate imaging in Hodgkin's disease: Final report of cooperative group. J Nucl Med 1977;18:692-698.
33. Nasr A, Stulberg J, Weitzman S, et al. Assessment of residual posttreatment masses in Hodgkin's disease and the need for biopsy in children. J Pediatr Surg 2006;41:972-974.
34. Larcos G, Farlow DC, Antico VF, et al. The role of high dose 67-gallium scintigraphy in staging untreated patients with lymphoma. Aust NZ J Med 1994;24:5-8.
35. Kaste SC, Howard SC, McCarville EB, et al. 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's. Pediatr Radiol 2005;35:141-154.
36. Beker DB, Berrak SG, Canpolat C, et al. False positivity of FDG-PET/CT in a child with Hodgkin disease. Pediatr Blood Cancer 2008;50:881-883.
37. Yeung HW, Grewal RK, Gonen M, et al. Patterns of (18)F-FDG uptake in adipose tissue and muscle: A potential source of false-positives for PET. J Nucl Med 2003;44:1789-1796.
38. Sandherr M, von Schilling C, Link T, et al. Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol 2001;12:719-722.
39. Weinblatt ME, Zanzi I, Belakhlef A, et al. False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med 1997;38:888-890.
40. Hutchings M, Loft A, Hansen M, et al. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 2007;78:206-212.
41. Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514-1523.
42. Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43:1018-1027.
43. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160-1168.
44. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-4471.
45. Maisey NR, Hill ME, Webb A, et al. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000;36:200-206.
46. Salloum E, Brandt DS, Caride VJ, et al. Gallium scans in the management of patients with Hodgkin's disease: A study of 101 patients. J Clin Oncol 1997;15:518-527.